Innovent Appoints Renowned Oncology Leader Dr. Nageatte Ibrahim as CMO


Innovent Biologics, Inc., a leading biopharmaceutical company, is pleased to announce the appointment of Dr. Nageatte Ibrahim as the company’s new Oncology Chief Medical Officer (CMO). With an impressive track record in the pharmaceutical industry, Dr. Ibrahim brings a wealth of expertise in oncology clinical development to her new role at Innovent.

As a renowned leader in the field, Dr. Ibrahim has made significant contributions to the advancement of cancer treatments throughout her career. Her extensive knowledge and experience will be invaluable in guiding Innovent’s oncology pipeline and clinical development strategies.

Dr. Ibrahim’s appointment reinforces Innovent’s commitment to developing innovative and effective therapies for cancer patients worldwide. Under her leadership, the company aims to accelerate the progress of its oncology programs and deliver cutting-edge solutions to address unmet medical needs in the fight against cancer.